Zacks Small Cap Decreases Earnings Estimates for Longeveron

Longeveron Inc. (NASDAQ:LGVN) – Equities researchers at Zacks Small Cap dropped their FY2025 EPS estimates for shares of Longeveron in a research note issued on Monday, March 3rd. Zacks Small Cap analyst B. Sorensen now forecasts that the company will post earnings per share of ($1.84) for the year, down from their prior estimate of ($1.28). The consensus estimate for Longeveron’s current full-year earnings is ($3.69) per share.

Other equities analysts have also issued reports about the company. Roth Capital upgraded Longeveron to a “strong-buy” rating in a research note on Thursday, December 5th. Roth Mkm initiated coverage on Longeveron in a research report on Friday, December 6th. They issued a “buy” rating and a $10.00 price target on the stock. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Longeveron in a research report on Monday.

Longeveron Price Performance

Longeveron stock opened at $1.44 on Wednesday. Longeveron has a fifty-two week low of $0.77 and a fifty-two week high of $6.40. The firm has a fifty day moving average price of $1.64 and a two-hundred day moving average price of $1.89. The firm has a market cap of $21.37 million, a price-to-earnings ratio of -0.23 and a beta of 0.37.

Institutional Investors Weigh In On Longeveron

Hedge funds have recently made changes to their positions in the stock. State Street Corp acquired a new position in Longeveron in the 3rd quarter valued at approximately $29,000. Northern Trust Corp acquired a new stake in shares of Longeveron during the 4th quarter worth approximately $31,000. Jane Street Group LLC bought a new stake in shares of Longeveron during the fourth quarter valued at approximately $35,000. Virtu Financial LLC acquired a new position in shares of Longeveron in the fourth quarter valued at $53,000. Finally, Geode Capital Management LLC lifted its position in Longeveron by 316.0% in the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock worth $250,000 after purchasing an additional 97,953 shares during the period. Institutional investors own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.